| Name | Title | Contact Details |
|---|
Theken Spine is a Akron, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Miami Medical is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
iCRco is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Drive DeVilbiss is committed to bringing to market a superior suite of products that focuses on innovation and design while improving the quality of life and promoting the independence for the individuals that use our durable medical equipment. Drive is dedicated to their customers by continually offering the highest quality and most functional products across a broad spectrum of health care needs, products that are a better value and competitively priced delivered by a team of world-class professionals. Drive’s complete line of products enhances the life of each user, from the mobility, bariatric, pressure prevention, self-assist, rehabilitation, pediatric products, to our wheelchairs, sleep surfaces, beds, respiratory equipment, power scooters, patient room equipment, to our electrotherapy devices and personal care products. We are the fastest growing global manufacturers of durable medical equipment; our products are used and distributed throughout North America, Europe, Central America, South America, the Middle East and Asia. Our market spans many verticals including: home healthcare providers, healthcare distributors, retailers, and e-tailers. Our recent expansion includes a new Long-Term Care Division and a new Acute Care Division. These developments are accompanied by the continued growth in the core home health care business. The corporate and distribution offices extend across the United States, Canada, United Kingdom, Germany, Romania, China and Taiwan.
Driven to raise the standard of care and improve the lives of patients with brain tumors, a team of brain tumor specialists formed GT Medical Technologies. FDA-cleared GammaTile Therapy is a Surgically Targeted Radiation Therapy (STaRT) for patients undergoing brain tumor removal surgery of newly diagnosed malignant and recurrent brain tumors. This "one-and-done" treatment eliminates the need for one to six weeks of daily external beam radiation therapy, allowing patients to go about their daily lives without the burden of additional trips to the hospital or clinic for ongoing treatment. Since its full market release in the United States in March 2020, GammaTile has been offered in more than 95 hospitals, with more centers being added each month.